Traws Pharma, Inc. provided a business update on March 31, 2025, highlighting its progress and financial outlook. The company reported that its cash runway is projected to support planned operations into the first quarter of 2026.
The update emphasized the potential of tivoxavir marboxil as a single-dose therapeutic agent for bird flu, supported by significant antiviral activity observed in three well-accepted animal models and positive Phase 1 data. This progress underscores the drug's potential in addressing pandemic threats.
Traws Pharma also confirmed ongoing interactions with the FDA to align on the path forward for tivoxavir marboxil, including discussions regarding the potential for accelerated approval utilizing the “Animal Rule.” These regulatory engagements are crucial for expediting the drug's development and potential market entry.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.